Standout Papers

A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy 2024 202641
  1. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy (2024)
    Richard Lafayette, Sean Barbour et al. Kidney International

Immediate Impact

1 by Nobel laureates 53 standout
Sub-graph 1 of 24

Citing Papers

Adipokines: masterminds of metabolic inflammation
2024 Standout
Glomerulonephritis: immunopathogenesis and immunotherapy
2023 Standout
3 intermediate papers

Works of Richard Phoon being referenced

IL-23, not IL-12, Directs Autoimmunity to the Goodpasture Antigen
2009
T-bet Deficiency Attenuates Renal Injury in Experimental Crescentic Glomerulonephritis
2008

Author Peers

Author Last Decade Papers Cites
Richard Phoon 259 46 80 165 80 25 576
Netar P. Mallick 419 40 79 175 28 27 671
Dustin J. Little 264 99 96 111 29 53 650
Julie Owen 126 82 139 117 39 22 561
James Wick 117 91 54 53 81 34 536
Seung Jun Kim 342 14 110 60 28 18 655
Sebastian E. Sattui 154 158 114 77 31 50 728
Melissa West 235 64 138 42 33 23 513
Zaki Morad 382 168 42 46 53 35 675
Fiona Braddon 199 37 51 30 74 25 698
Mark Thomas 136 44 52 38 32 38 540

All Works

Loading papers...

Rankless by CCL
2026